dopamine and norepinephrine reuptake inhibition via d and l amphetamine enantiomers clinical trial intelligence

A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder

SHP465, a formulation of amphetamine salts, is being evaluated for safety and pharmacokinetics in a pediatric population (ages 4-5) with ADHD. The market for ADHD treatments is substantial, with increasing demand for effective therapies in younger populations. The completion of this Phase 1 trial positions Shire (now part of Takeda) to further explore the therapeutic potential of SHP465, particularly in a demographic that has limited treatment options. Competitive implications include the need to monitor existing ADHD medications and emerging therapies targeting similar patient populations. Diligence should focus on the safety profile and potential market entry strategies, given the stringent regulatory environment for pediatric medications.

Matched by target_normalized: Dopamine and norepinephrine reuptake inhibition via d- and l-amphetamine enantiomers.